BYND Cannasoft Enterprises announced a new plan of work that focuses on its proprietary CRM platform in an effort to help meet the increased demand for medical cannabis in Israel. Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort. Israel has had a significant increase in the number of licensed medical cannabis patientsii in the wake of recent events, particularly the opening of the war in Gaza. This surge has resulted in more than 2,000 new patients in just one month, approaching the peak numbers of 2021 and bringing the total number to over 132,000 as of November 2023. BYND Cannasoft’s proprietary Benefit CRM enables small and medium-sized enterprises to optimize day-to-day functions, such as sales management, workforce management, contact center operations, and asset management. Benefit CRM is provisioned as SaaS to some of Israel’s most recognizable companies. As part of the new plan of work, the software development phase will focus on innovative elements in the field of artificial intelligence that will increase their data collection and analysis. Physicians licensed to prescribe medical cannabis and Israeli Ministry of Health authorities have reported a notable surge in demand after the recent conflict. There is a burgeoning presence of initiatives by both corporate entities and private individuals aimed at providing cannabis to individuals residing in the southern region. The increasing trend comes after a period of data stagnation in the first half of the year. The Israeli medical community is experiencing a tremendous increase in the number of patients seeking treatment for post-trauma, marking a significant shift from the previous decline in this category. In February 2023, BYND Cannasoft announced that the Medical Cannabis Unit at the Ministry of Health of the State of Israel issued the Company a full license to engage in medical cannabis without direct contact with the substance. This license allows BYND Cannasoft to trade in medical cannabis products through an agreement with a licensed cannabis grower in Israel. The recent increase in patients seeking treatment for post-trauma, which had seen a decline in the past year, adds significant value to this license, as well as BYND Cannasoft’s proprietary CRM platform. Many of the medical cannabis patients receiving new licenses are war casualties, as doctors began issuing licenses for post-trauma to victims of the recent events. In terms of patient age, more than 60,000 medical cannabis patients in Israel, nearly half of the total, fall in the 21-45 age range. The second-largest group comprises approximately 44,000 patients aged 46-65, with the remaining 24,000 patients aged 66 and over. There is also a smaller percentage of patients up to the age of 20, particularly children with conditions like autism or epilepsy. The data also indicate an increase in patients using relatively high doses, with 29,752 patients holding a license for 40 grams of cannabis per month, 27,382 patients for 50 grams, and 25,709 patients for 20 grams. Additionally, 20,516 patients have licenses for 30 grams, 13,211 for 60 grams, and about 15,000 patients for 70 grams per month or more.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCAN: